CD8A and metabolic dysfunction-associated steatotic liver disease: Furthermore, STM2457 plus anti-PD-1 treatment most strongly induced IFN-γ+ and GZMB+ CD8+ T cells in NAFLD-HCC tumors (Figure 7M).